
A
Mouse tumor growth after CAR T treatment
RV-CAR Tumor Growth
VFC-CAR Tumor Growth
VFC-Ctrl Tumor Growth
Flux(p/s)
Days post-CAR T treatment
B
Mouse weight change after CAR T treatment
VFC-Ctrl
RV-CAR
VFC-CAR
Individual % weight change
Average % weight change
Days post-CAR T treatment
C
Flow cytometry gating strategy (spleens, Fig. 8E and F)
RV Spleen
Lymphocytes
60.3%
SSC-H (RFU)
FSC-H (RFU)
RV Spleen
Lymphocytes
Single Cells
66.8%
RV Spleen
Lymphocytes
Single Cells
Live
55.4%
Viability (RFU)
RV Spleen
Lymphocytes
Single Cells
Live
mCD45⁻ hCD45⁺
32.4%
mCD45 (RFU)
hCD45 (RFU)
RV Spleen
Lymphocytes
Single Cells
Live
mCD45⁻ hCD45⁺
CAR⁺
34.3%
CAR⁻
65.7%
CAR (RFU)
FSC-H (RFU)
CAR FMO Control
Lymphocytes
Single Cells
Live
mCD45⁻ hCD45⁺
CAR (RFU)
FSC-A (RFU)
D
T cell immunophenotyping *in vivo*: spleen
Tn
(all hCD45+ cells)
Tscm and Tcm
(all hCD45+ cells)
% CD62L+/CD95−/CCR7+ (CD45+)
% CD62L+/CD95+/CCR7+ (CD45+)
RV-CAR
VFC-CAR
VFC-Ctrl
Tn
(hCD45+/CAR+ T cells)
Tscm and Tcm
(hCD45+/CAR+ T cells)
% CD62L+/CD95−/CCR7+ (CD45+/CAR+)
% CD62L+/ CD95+/ CCR7+ (CD45+) CAR+